Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17887994 | 0.93 | SMN1; SMN2 (0.77) | SMN1; SMN2RAB9ANPC1LMNAHTT | |
| SCHEMBL18193848 | 0.88 | NPC1 (0.67) | SMN1; SMN2RAB9ANPC1LMNAHDAC2 | |
| SCHEMBL14297350 | 0.86 | NPC1 (0.69) | SMN1; SMN2RAB9ANPC1LMNAHTT | |
| SCHEMBL17301589 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1LMNAHDAC6 | |
| SCHEMBL24648929 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1LMNAHTT | |
| SCHEMBL5943961 | 0.85 | SMN1; SMN2 (0.71) | SMN1; SMN2RAB9ANPC1LMNAHDAC6 | |
| SCHEMBL10099572 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2RAB9ANPC1LMNAHTT | |
| SCHEMBL10099552 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2RAB9ANPC1LMNAHTT | |
| SCHEMBL3705474 | 0.84 | RAB9A (0.67) | SMN1; SMN2RAB9ANPC1LMNAHDAC6 | |
| SCHEMBL496789 | 0.84 | SMN1; SMN2 (0.81) | SMN1; SMN2RAB9ANPC1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | LESER-REIFF ULRIKE | 2004-10-28 | — | — | US | claimed |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-16 | — | — | US | claimed |
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | LESER-REIFF ULRIKE | 2004-10-28 | — | — | US | disclosed |
| US-6784173-B2 | ANTIPROLIFERATIVE AGENTS; ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1401824-A2 | AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003011851-A2 | AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-02-13 | — | — | WO | disclosed |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | HDAC1, HDAC2, HDAC11 | SMN1; SMN2 3558/4885RAB9A 3059/4885NPC1 2721/4885 |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HDAC1, HDAC2, HDAC11 | SMN1; SMN2 3558/4885RAB9A 3059/4885NPC1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.